Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
29/09/2026 12:03
BRIEF-Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate Sept 29 (Reuters) - Immix Biopharma, Inc. IMMX.O:
IMMIX BIOPHARMA ANNOUNCES 89% COMPLETE RESPONSE RATE AT INTERIM UPDATE ACROSS ALL NEXICART-2 PATIENTS, WITH MRD-NEGATIVITY INDICATING POTENTIAL TO REACH UP TO 98% COMPLETE RESPONSE RATE, SUPPORTING POTENTIAL BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS
IMMIX BIOPHARMA, - 100% OF NEW NEXICART-2 PATIENTS IN COMPLETE RESPONSE OR MRD-NEGATIVE
IMMIX BIOPHARMA, - NEXICART-2 FINAL READOUT AND BLA SUBMISSION PLANNED FOR MID-2027
Source text: ID:nGNX12c7nH
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary